Sacituzumab govitecan
About
Therapy type: Targeted therapy
Therapy strategy: Topoisomerase inhibition
Mappings
NCI Thesaurus: Sacituzumab Govitecan (ncit:C102783)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | ER positive, HER2-negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | ER positive, HER2-negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Sacituzumab govitecan |